News, Articles & Press Releases
-
April 10, 2025Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors
-
April 01, 2025
Cellares’ Cell Shuttle Receives FDA Advanced Manufacturing Technology (AMT) Designation for Automated Cell Therapy Manufacturing
-
March 19, 2025
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform
-
November 12, 2024
Cellares Appoints Ossama Eissa, Former Novartis, Lonza, and Legend Biopharma Leader as Chief Operating Officer
-
September 12, 2024
Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform
-
September 05, 2024
Cellares Announces Completion of First cGMP Cell Shuttle at IDMO Smart Factory in Bridgewater, New Jersey
-
September 03, 2024
Cellares Appoints Justin McAnear as CFO and Jonathan Butler as General Counsel
-
June 27, 2024
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
-
June 03, 2024
Live From MarketSite: Cellares CEO and Co-Founder, Fabian Gerlinghaus Interviewed by Nasdaq Listings Host Kristina Ayanian on Cellares’ $380M Worldwide Capacity Reservation and Supply Agreement with Bristol Myers Squibb
-
April 22, 2024
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
-
April 18, 2024
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
-
March 26, 2024
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
-
March 12, 2024
Cellares Unveils First cGMP Compliant Cell Shuttle in its South San Francisco Center of Excellence
-
November 06, 2023
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
-
October 24, 2023
Live from MarketSite: Cellares CEO and Co-Founder, Fabian Gerlinghaus Interviewed by Nasdaq Listings Host Kristina Ayanian on how Cellares’ purpose-built technology powers the first Integrated Development & Manufacturing Organization (IDMO)
-
October 11, 2023
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program
-
October 10, 2023
Exclusive: Cellares expands deal with Bristol Myers on preclinical CAR-T asset, eyes manufacturing expansion
-
September 11, 2023
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
-
August 28, 2023
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
-
August 23, 2023
Exclusive: Bloomberg Technology’s Ed Ludlow Interviews Cellares’ CEO and Co-founder, Fabian Gerlinghaus on Company’s Massive $255M Series C Up-Round
-
August 23, 2023
Fabian Gerlinghaus, Cellares CEO & Co-Founder, Unveils the Launch of the World’s First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies
-
August 23, 2023
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies
-
January 18, 2023
As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing
-
January 11, 2023
Automated Manufacturing Will Deliver More—and Better—Cell Therapies
-
November 14, 2022
Business Insider
-
October 06, 2022
Will Manufacturing Be the Stumbling Block for T-Cell Therapies?
-
September 20, 2022
Cellares to tackle key roadblock in cell therapy manufacturing with new partner iVexSol
-
May 04, 2022
Fabian Gerlinghaus recognized in Medicine Maker Power List 2022
-
April 26, 2022
Drug Discovery & Development
-
November 16, 2021
Cellares Appoints Ezekiel Emanuel to Board of Advisors
-
November 11, 2021
Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy
-
October 27, 2021
Fabian Gerlinghaus receives 2021 Life Science Catalyst Award
-
October 11, 2021
Cellares Appoints John Tomtishen as Vice President of Operations
-
July 28, 2021
Forbes
-
July 14, 2021
Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy
-
July 14, 2021
Fierce Pharma
-
July 14, 2021
GeneOnline
-
July 14, 2021
Drug Discovery & Development
-
July 14, 2021
Endpoints
-
July 14, 2021
BioProcess International
-
May 06, 2021
Fierce Pharma
-
May 05, 2021
Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing
-
May 05, 2021
Reuters
-
May 05, 2021
Endpoints
-
May 05, 2021
Crunchbase
-
May 05, 2021
MedCity News
-
April 26, 2021
BioProcess International
-
April 15, 2021
Fabian Gerlinghaus featured in Medicine Maker Power List 2021
-
February 11, 2021
Cellares Appoints Dr. Rodney L. Rietze to Advisory Board
-
February 08, 2021
CAR-T Sector Seeks Tech Boost to Meet Anticipated Demand
-
January 25, 2021
Spearheading a Paradigm Shift in Cell Therapy Manufacturing
-
January 08, 2021
Cellares Adds PACT Pharma to its Early Access Partnership Program
-
October 29, 2020
Cellares Welcomes Fred Hutchinson Cancer Research Center Into Its Early Access Partnership Program
-
October 29, 2020
Cellares – Evolving the Pharmaceutical Manufacturing Industry
Media Kit
